58 Biggest Movers From Friday
Gainers
Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
BeiGene’s Pediatric Tumor Drug Scores Conditional Approval In China
The China National Medical Products Administration (NMPA) granted conditional approval for BeiGene Ltd (NASDAQ: BGNE) – EUSA Pharma’s (UK) Qarziba (dinutuximab beta) in high-risk neuroblastoma…
Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $407
Morgan Stanley analyst Matthew Harrison maintains BeiGene (NASDAQ:BGNE) with a Overweight and lowers the price target from $409 to $407.
Unusual Options Activity Insight: BeiGene
BeiGene (NASDAQ:BGNE) shares experienced unusual options activity on Wednesday. The stock price moved down to $281.92 following the option alert.
BeiGene Q2 EPS $(5.23) Down From $(4.31) YoY, Sales $149.99M Up From $65.64M YoY
BeiGene (NASDAQ:BGNE) reported quarterly losses of $(5.23) per share. This is a 21.35 percent decrease over losses of $(4.31) per share from the same period last year. The company reported $149.99 million in sales this
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
BeiGene’s Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
Health Canada has approved BeiGene Ltd (NASDAQ:BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients…